Description

Simple

Clinical

Overview

Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.

Pharmacology

Indication

For the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.

Pharmacodynamic

Vapreotide is a somatostatin analog with a higher metabolic stability than the parent hormone. Vapreotide reduces splanchnic blood flow; inhibits growth hormone release, and inhibits the release of peptides and vasoactive compounds from neuroendocrine tumors.

Mechanism of action

The exact mechanism of action is unknown, although one study has provided in vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect in the analgesic effects of vapreotide (PMID: 7556407).

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

30 minutes

Route of elimination

Vapreotide is 76% eliminated in bile. The remainder is renally eliminated.

Toxicity

Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Vapreotide
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Vapreotide.
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Vapreotide.
4-hydroxycoumarin
The metabolism of 4-hydroxycoumarin can be decreased when combined with Vapreotide.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be decreased when combined with Vapreotide.
Acenocoumarol
The serum concentration of Acenocoumarol can be increased when it is combined with Vapreotide.
Albendazole
The metabolism of Albendazole can be decreased when combined with Vapreotide.
Alfentanil
The metabolism of Alfentanil can be decreased when combined with Vapreotide.
Alfuzosin
The metabolism of Alfuzosin can be decreased when combined with Vapreotide.
Allylestrenol
The metabolism of Allylestrenol can be decreased when combined with Vapreotide.
Alpelisib
The metabolism of Alpelisib can be decreased when combined with Vapreotide.
Alprazolam
The metabolism of Alprazolam can be decreased when combined with Vapreotide.
Aminophylline
The metabolism of Aminophylline can be decreased when combined with Vapreotide.
Amiodarone
The metabolism of Amiodarone can be decreased when combined with Vapreotide.
Aripiprazole
The metabolism of Aripiprazole can be decreased when combined with Vapreotide.
Aripiprazole lauroxil
The metabolism of Aripiprazole lauroxil can be decreased when combined with Vapreotide.
Artesunate
The metabolism of Artesunate can be decreased when combined with Vapreotide.
Astemizole
The metabolism of Astemizole can be decreased when combined with Vapreotide.
Atazanavir
The metabolism of Atazanavir can be decreased when combined with Vapreotide.
Atorvastatin
The metabolism of Atorvastatin can be decreased when combined with Vapreotide.
Azithromycin
The metabolism of Azithromycin can be decreased when combined with Vapreotide.
7 References
  1. 1 . Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565.PubMed: 12691930
  2. 2 . Authors unspecified: Vapreotide: BMY 41606, RC 160, Sanvar. Drugs R D. 2003;4(5):326-30.PubMed: 12952505
  3. 3 . Norman P: Vapreotide (Debipharm). IDrugs. 2000 Nov;3(11):1358-72.PubMed: 16047258
  4. 4 . Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A: Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther. 1994 Apr;269(1):7-14.PubMed: 7909563
  5. 5 . Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV: Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul;6(7):715-8.PubMed: 1354449
  6. 6 . Stiefel F, Morant R: Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer. 1993 Jan;1(1):57-8.PubMed: 7511473
  7. 7 . Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J: Seven-day antinociceptive effect of a sustained release vapreotide formulation. Neuroreport. 1994 Jan 31;5(5):642-4.PubMed: 7912964